News | Embolic Protection Devices | August 06, 2019

Cardiovascular Systems Inc. Acquires Gardia Medical Ltd.'s Wirion Embolic Protection System

Wirion System captures debris associated with peripheral vascular interventions

Cardiovascular Systems Inc. Acquires Gardia Medical Ltd.'s Wirion Embolic Protection System

August 6, 2019 — Cardiovascular Systems Inc. (CSI) has acquired the Wirion Embolic Protection System and related assets from Gardia Medical Ltd., a wholly owned Israeli subsidiary of Allium Medical Solutions Ltd.

The device, which received European CE Mark in June 2015 and U.S. Food and Drug Administration (FDA) clearance in March 2018, is a distal embolic protection filter used to capture debris that can be associated with all types of peripheral vascular intervention (PVI) procedures. Physicians typically use embolic protection devices in vessels located above the knee with long lesions, high plaque burden and poor run off.

Ehrin Armstrong, M.D., professor of medicine at the University of Colorado, said, “The use of an embolic protection device during peripheral interventions where the risk of embolization is higher provides assurance and protection from procedural complications.”

The Wirion System is easier to use and more versatile than other available embolic protection systems, according to the company, because it can be used with any .014-inch guidewire and for all types of peripheral interventions. In addition, the Wirion System is the only embolic protection device indicated for use with any atherectomy system. The WISE LE study also demonstrated a major adverse event (MAE) rate of 1.9 percent, which is lower than any other previously reported rates with other embolic filters. No clinically significant distal embolization was observed when the Wirion System was used.

WISE LE (Wirion EPS in Lower Extremities Arteries) was a multicenter study, performed in the United States and Germany and included all commercially available atherectomy systems. The primary endpoint was freedom from MAEs occurring within 30 days post-procedure and was compared with an objective performance goal derived from historical atherectomy trials. MAE was defined as a serious adverse event that resulted in death, acute myocardial infarction, thrombosis, pseudoaneurysm, dissection (grade C or greater) or clinical perforation at the filter location, clinically relevant distal embolism, unplanned amputation or clinically driven target vessel revascularization. The study also included a histopathological analysis of debris captured by the filter during the procedures.

CSI plans to commercialize the Wirion System in the U.S. following the transfer of manufacturing from Gardia Medical. CSI expects the manufacturing transfer to be completed after a 12- to 15-month transition period. Gardia will retain the rights to the Wirion System for angioplasty and stenting procedures in the carotid arteries.

For more information: www.csi360.com, www.allium-medical.com

Related Embolic Protection Device Content

VIDEO: Defining the Need for TAVR Embolic Protection

FDA Clears First TAVR Embolic Protection System

Related Content

The Rex Medical Revolution rotational atherectomy system incorporates continuous aspiration and has a dual indication for atherectomy and thrombectomy.  #VICA19 #VIVA2019

The Rex Medical Revolution rotational atherectomy system incorporates continuous aspiration and has a dual indication for atherectomy and thrombectomy. 

News | Atherectomy Devices | November 11, 2019
November 7, 2019 — The REVEAL FDA investigational device exemption (IDE) trial confirmed a favorable safety and effec
The AngioDynamics/Eximo Medical B-Laser represents a new atherectomy device. #VIVA2019 #VIVA #VIVA19

The AngioDynamics/Eximo Medical B-Laser atherectomy system.

News | Atherectomy Devices | November 07, 2019
November 7, 2019 — There was no difference between drug-coated balloons (DCB) vs.
Rex Medical Receives 510(k) Clearance for Revolution Peripheral Atherectomy System
Technology | Atherectomy Devices | September 13, 2019
Rex Medical L.P. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Revolution...
First U.S. Patients Treated With Second-Generation Pantheris Atherectomy Device
News | Atherectomy Devices | July 18, 2018
Avinger Inc. announced in June that several physicians have successfully treated over 40 patients for peripheral artery...
Avinger Receives FDA Clearance of Next-Generation Pantheris Device
Technology | Atherectomy Devices | May 24, 2018
Avinger Inc. announced that the company received 510(k) clearance from the U.S. Food & Drug Administration (FDA)...
Medtronic Receives FDA Clearance for Riptide Aspiration System
Technology | Atherectomy Devices | January 16, 2018
Medtronic plc announced the company’s Neurovascular business unit received U.S. Food and Drug Administration (FDA)...
Avinger Announces Treatment of First Patients With Next-Generation Pantheris
News | Atherectomy Devices | January 09, 2018
January 9, 2018 – Avinger Inc. announced that Arne Schwindt, M.D., a vascular surgeon at St.
Avinger Receives 510(k) Clearance for Pantheris Image-Guided Atherectomy Device Modifications
Technology | Atherectomy Devices | November 20, 2017
November 20, 2017 — Avinger Inc. announced in October that the company received 510(k) clearance from the U.S.
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices | September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Ra Medical Systems Receives FDA Clearance for New Peripheral Artery Disease Treatment
Technology | Atherectomy Devices | May 30, 2017
The U.S. Food and Drug Administration (FDA) announced that it has granted market clearance to Ra Medical Systems for...
Overlay Init